GLP-1 for Low Blood Sugar

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: University of Maryland, Baltimore

Trial Summary

What is the purpose of this trial?

Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.

Research Team

Stephen N. Davis, MBBS

Principal Investigator

University of Maryland, Baltimore

Eligibility Criteria

This trial is for adults aged 30-60 with Type 2 Diabetes who have a body mass index over 25 and controlled blood sugar levels (HbA1c between 6-10%). It's also open to healthy individuals in the same age range. People with significant diabetic complications like retinopathy or neuropathy can't participate.

Inclusion Criteria

I am a healthy individual aged 30-60.

I do not have major complications from diabetes like eye or nerve damage.

You weigh more than what is considered healthy for your height.

Treatment Details

Interventions

• Glucagon-Like Peptide-1 (GLP-1) (GLP-1 Agonist)

Trial Overview The study is testing whether GLP-1, a hormone that occurs naturally in the gut, can reduce negative effects of low blood sugar on blood vessels. Participants will receive either GLP-1 infusion or saline as a placebo to compare outcomes.

Participant Groups

Group I: Glucagon-Like Peptide -1 (GLP-1) infusion Active Control 1 Intervention

Infusion of GLP-1 during experimental period

Group II: Saline Infusion Placebo Group 1 Intervention

Saline infusion during experimental period

Who Is Running the Clinical Trial?

University of Maryland, Baltimore

Lead Sponsor

Trials

729

Recruited

540,000+